Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.)have demonstrated clinical proof of concept for cancer treatment. Here, PARP1 is linked to cancer.